Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$181.89 -2.6%	$186.21	$163.52 ▼ $218.66	$321.29B	0.5	6.25 million shs	29.26 million shs
LLY Eli Lilly and Company	$776.18 -2.4%	$780.19	$677.09 ▼ $972.53	$735.61B	0.41	3.68 million shs	4.11 million shs
MRK Merck & Co., Inc.	$78.93 +0.1%	$79.06	$73.31 ▼ $129.93	$198.20B	0.38	13.16 million shs	60.17 million shs
PFE Pfizer	$24.20 -0.2%	$23.46	$20.92 ▼ $31.54	$137.56B	0.57	41.37 million shs	39.50 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	-1.77%	-1.96%	-13.32%	+6.04%
LLY Eli Lilly and Company	0.00%	+1.67%	+5.13%	-5.97%	-14.27%
MRK Merck & Co., Inc.	0.00%	-0.40%	+2.69%	-12.05%	-36.24%
PFE Pfizer	0.00%	+0.95%	+3.14%	-4.57%	-13.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.958 of 5 stars	3.4	5.0	4.2	3.9	3.0	2.5	1.3
LLY Eli Lilly and Company	4.983 of 5 stars	4.4	4.0	3.3	4.0	2.8	1.7	1.9
MRK Merck & Co., Inc.	4.9948 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
PFE Pfizer	4.8658 of 5 stars	2.3	3.0	4.2	4.3	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	16.16% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	30.33% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	38.33% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.54% Upside

Current Analyst Ratings Breakdown

Latest PFE, ABBV, LLY, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/2/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,050.00
5/1/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.70	$14.90 per share	12.21	$1.90 per share	95.73
LLY Eli Lilly and Company	$45.04B	16.33	$14.25 per share	54.48	$15.03 per share	51.64
MRK Merck & Co., Inc.	$64.17B	3.09	$9.44 per share	8.36	$18.33 per share	4.31
PFE Pfizer	$63.63B	2.16	$4.37 per share	5.54	$15.62 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	77.40	13.01	1.21	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	63.16	24.94	1.13	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.49	7.97	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.53	7.99	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest PFE, ABBV, LLY, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.61%	N/A	279.15%	53 Years
LLY Eli Lilly and Company	$6.00	0.77%	N/A	48.82%	11 Years
MRK Merck & Co., Inc.	$3.24	4.10%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	7.11%	N/A	124.64%	16 Years

Latest PFE, ABBV, LLY, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
LLY Eli Lilly and Company	2.18	1.37	1.06
MRK Merck & Co., Inc.	0.69	1.41	1.16
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.41 million	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, ABBV, LLY, and MRK Headlines

Recent News About These Companies

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

4 hours ago | investing.com

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

5 hours ago | prnewswire.com

Essex Financial Services Inc. Sells 31,049 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 7:23 AM | marketbeat.com

KBC Group NV Purchases 199,736 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 7:07 AM | marketbeat.com

Cohen Investment Advisors LLC Grows Stake in Pfizer Inc. (NYSE:PFE)

June 29 at 6:33 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 29 at 5:05 AM | marketbeat.com

Creative Financial Designs Inc. ADV Sells 32,370 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 4:16 AM | marketbeat.com

GAMMA Investing LLC Acquires 25,785 Shares of Pfizer Inc. (NYSE:PFE)

June 29 at 3:03 AM | marketbeat.com

Pfizer’s HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study

June 29 at 2:17 AM | insidermonkey.com

Pfizer’s Bold Clinical Trials Could Boost Stock Performance

June 28 at 11:25 AM | tipranks.com

Sumitomo Mitsui Trust Group Inc. Sells 941,490 Shares of Pfizer Inc. (NYSE:PFE)

June 28 at 8:17 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Sunbelt Securities Inc.

June 28 at 6:56 AM | marketbeat.com

Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment

June 28 at 6:38 AM | msn.com

3 No-Brainer Stocks to Buy for Under $100 Right Now

June 28 at 6:35 AM | fool.com

BSW Wealth Partners Acquires 17,274 Shares of Pfizer Inc. (NYSE:PFE)

June 28 at 6:30 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by QSM Asset Management Ltd

June 28 at 5:44 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Achmea Investment Management B.V.

June 28 at 5:26 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Illinois Municipal Retirement Fund

June 28 at 5:17 AM | marketbeat.com

Perpetual Ltd Grows Stake in Pfizer Inc. (NYSE:PFE)

June 28 at 4:46 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Holdings Lifted by Bessemer Group Inc.

June 28 at 4:03 AM | marketbeat.com

Pfizer reports positive results from Phase III BAISIS trial for haemophilia

June 27 at 8:37 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Best Dollar Store Stock to Buy: Dollar Tree or Dollar General?
By Thomas Hughes | June 5, 2025
View Best Dollar Store Stock to Buy: Dollar Tree or Dollar General?
Why SoundHound Could Be a Short Squeeze in the Making
By Gabriel Osorio-Mazilli | June 2, 2025
View Why SoundHound Could Be a Short Squeeze in the Making

PFE, ABBV, LLY, and MRK Company Descriptions

AbbVie NYSE:ABBV

$181.89 -4.90 (-2.62%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$182.78 +0.89 (+0.49%)

As of 06/27/2025 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$776.18 -18.94 (-2.38%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$774.90 -1.28 (-0.16%)

As of 06/27/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$78.93 +0.10 (+0.13%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$79.00 +0.07 (+0.10%)

As of 06/27/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.20 -0.04 (-0.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$24.18 -0.02 (-0.07%)

As of 06/27/2025 08:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time